OBJECTIVES The aim of this study was to characterize the association between decongestion therapy and 30-day outcomes in patients hospitalized for heart failure (HF).
C ongestive signs and symptoms related to excess total body sodium and water are common in patients with heart failure (HF) despite the use of chronic diuretic therapy (1) . Current guidelines recommend adjustment of diuretic agent doses as needed to increase renal sodium and water excretion in patients with clinical evidence of congestion with the goal of achieving a euvolemic state (2, 3) .
Factors that may contribute to need for higher diuretic agent doses to maintain clinical euvolemia include excess dietary sodium intake, altered gastrointestinal absorption of oral diuretic agents, decreased secretion of loop diuretic agents into the nephron, comorbid renal insufficiency, and glomerular and renal tubular changes that limit the increase in fractional sodium excretion in response to loop diuretic agents (4, 5) .
Although loop diuretic agents are the most commonly used class of drugs for the treatment of congestive signs and symptoms (1) , the effects of diuretic agents on clinical outcomes in patients with HF remain uncertain. Several prior studies have demonstrated an association between higher dose diuretic agents and greater risk for adverse clinical outcomes in both outpatient and inpatient HF populations (6) (7) (8) (9) , with putative mechanisms of harm related to greater risk for arrhythmic death due to electrolyte depletion, hypovolemia, worsening renal function, and/or increased neurohormonal activation (4, 10, 11) . In contrast, other studies demonstrated that higher diuretic agent doses are associated with improved survival in hospitalized patients with HF with evidence of hemoconcentration in response to therapy (12) (13) (14) (15) .
Given these divergent data, we hypothesized that the relationship between diuretic agent dose and 
METHODS
The rationale, design, and main results of the EVEREST trial have been previously reported (16, 17) . In brief, CIs. Assumptions of proportional hazards were verified. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, North Carolina) at a conventional 2-tailed 5% significance level.
RESULTS BASELINE CHARACTERISTICS BY DIURETIC AGENT
EXPOSURE. Average daily diuretic agent dose during the first 72 h of hospitalization varied over a wide range in the 3,037 subjects with available loop diuretic agent dosing data ( Figure 1 ). Values are mean AE SD, n (%), or median (interquartile range). p values for comparisons between the 2 groups are reported. Subjects treated with average loop diuretic agent doses $160 mg/day had clinical characteristics consistent with more severe HF and had a higher frequency of comorbid medical conditions compared with those treated with average loop diuretic agent doses <160 mg/day.
HF ¼ heart failure.
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